Aerie Pharmaceuticals Inc. (NASDAQ: AERI) Stock Coverage Initiated at HC Wainwright

Analysts at HC Wainwright initiated coverage on Aerie Pharmaceuticals Inc. (NASDAQ: AERI) stock, starting the company at Buy. The company currently has a rating of Buy on the shares. A number of other analysts have issued reports on the stock in recent days, and the company has earned a consensus one-year price target of $50.25, higher than the opening price of $34.94, a difference of 13.30 percent. Aerie Pharmaceuticals Inc. stock has a 52-week high of $38.30. Changes in price targets are not unusual as analysts and brokerage firms will issue periodic updates after initiating coverage,.

U.S. stocks on Monday closed essentially flat, after trading firmly higher, in a volatile session ahead of the start of a pair of closely watched central-bank policy meetings.

The Dow Jones Industrial Average DJIA, -0.02% closed down 3.63 points at 18,120.17.

The blue-chip gauge had been up by as much as 131 points earlier and traded within a 162-point range.

The S&P 500 SPX, +0.00% slipped 0.04 points to close at 2,139.12, after trading within an 18-point range

Meanwhile, the Nasdaq Composite Index COMP, -0.18% declined 9.54 points, or 0.2%, to close at 5,235.03.

Earlier, the Nasdaq Composite Index had been up by as many as 37 points and traded with a 58-point range

Yesterday Aerie Pharmaceuticals Inc. (NASDAQ: AERI) shares last traded at $37.79, which represents an increase of $3.67 compared to the previous closing price. Opening at $34.94, they varied from $34.90 and $38.30 throughout the day.

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) currently has a market cap of 1.05B.

1,566,600 shares traded hands yesterday, 86 percent above normal, out of a total float 13,732,000. Heavy volume aggregation by institutional investors may be in the near future as the combination of large increases in trading volume and price inflation can be deciding components.

As with all possible breakouts, investors look for volume to be at least 40%-50% higher than normal on the breakout to show that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have substantial teams of analysts researching thousands of stocks. So watching their interests is a good way to make sure you are buying the right stocks.

By marking the activity of these professional investors—and the moving averages they influence—it allows for traders to make more useful choices on trades.

With that in mind, Aerie Pharmaceuticals Inc. (NASDAQ: AERI) now has a 50-day MA of $20.33 and 200-day MA of $16.95. It has traded in a 52-week range between $10.82 – 38.300 and today’s last price is 0.01% lower than the 52 week high of $38.30.

Earnings growth is an important factor to consider when buying stocks and investors seek companies that have raised their earnings at least 25% or more over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.